Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2017

01-11-2017 | Brief Research Article

Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer

Author: O. Abdel-Rahman

Published in: Clinical and Translational Oncology | Issue 11/2017

Login to get access

Abstract

Background

The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for non-small cell lung cancer (NSCLC) has been released. The current study tried to validate the prognostic significance of the new system among patients registered within the surveillance, epidemiology and end results (SEER) database.

Methods

SEER database (2010–2013) has been accessed through SEER*Stat program and AJCC 8th edition stages were reconstructed utilizing the collaborative stage descriptions. Overall and lung cancer-specific survival analyses according to both 7th and 8th editions were conducted through Kaplan–Meier analysis and multivariate analysis was conducted through a Cox proportional hazard model.

Results

A total of 127,096 patients with NSCLC were identified in the period from 2010 to 2013. For overall survival assessment according to the 8th edition, P values for all pair-wise comparisons among different stages were significant (<0.0001) except for the comparisons between stage IB and IIA (P = 0.146); stage IIA and IIB (P = 0.165). For lung cancer-specific survival according to the 8th edition, P values for all pair-wise comparisons among different stages were significant (<0.001). Among patients with stage I disease, multivariate analysis for factors affecting overall and lung cancer-specific survival among patients with stage I disease was conducted. The following factors were associated with worse overall and lung cancer-specific survival: age ≥70 years, more advanced stage, male gender, squamous histology, no surgery and no radiotherapy (P < 0.0001 for all factors).

Conclusion

This SEER analysis supports the prognostic significance of the added sub-stages described within AJCC 8th edition stages I and III. Further work is needed to incorporate molecular markers and personalize the future editions of the AJCC staging system.
Literature
1.
Globocan.iarc.fr. Last Accessed on 27 Nov 2016.
2.
Paleiron N, Bylicki O, André M, Rivière E, Grassin F, Robinet G, et al. Targeted therapy for localized non-small-cell lung cancer: a review. Onco Targets Ther. 2016;9:4099–104.CrossRefPubMedPubMedCentral
3.
4.
Abdel-Rahman O, Elhalawani H. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Futur Oncol. 2015;11(7):1109–22.CrossRef
5.
Sen F, Tambas M, Ozkaya K, Guveli ME, Ciftci R, Ozkan B, et al. Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. Medicine. 2016;95(30):e4280.CrossRefPubMedPubMedCentral
6.
Aggarwal C. Targeted therapy for lung cancer: present and future. Ann Palliat Med. 2014;3(3):229–35.PubMed
7.
Bansal P, Rusthoven C, Boumber Y, Gan GN. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. Futur Oncol. 2016;12(23):2713–27.CrossRef
8.
Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694–705.CrossRefPubMed
9.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRefPubMed
10.
11.
Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California cancer registry. J Thorac Oncol. 2008;3(3):216–27.CrossRefPubMed
12.
Zell JA, Ignatius Ou SH, Ziogas A, Anton-Culver H. Validation of the proposed International Association for the Study of lung cancer non-small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry. J Thorac Oncol. 2007;2(12):1078–85.CrossRefPubMed
13.
Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, et al. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015;10(4):682–90.CrossRefPubMedPubMedCentral
14.
Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol. 2012;7(10):1479–84.CrossRefPubMed
15.
Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7(33):53245–53.CrossRefPubMedPubMedCentral
Metadata
Title
Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer
Author
O. Abdel-Rahman
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 11/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1673-7

Other articles of this Issue 11/2017

Clinical and Translational Oncology 11/2017 Go to the issue

Research Article

Hangeshashinto (TJ-14) prevents radiation-induced mucositis by suppressing cyclooxygenase-2 expression and chemotaxis of inflammatory cells

Erratum

Erratum to: Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer

Research Article

The spine instability neoplastic score (SINS) in the assessment of response to radiotherapy for bone metastases

Research Article

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

Research Article

A logistic regression model predicting high axillary tumour burden in early breast cancer patients

Research Article

Improving efficacy and efficiency through the implementation of a new organisational model in a Radiation Oncology Department
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits